Bone Biologics Corp
Datakwaliteit: 83%
€ 1,26
▼
€ 0,02
(-1,56%)
Marktkapitalisatie: 2,26 M
Prijs
€ 1,26
Marktkapitalisatie
2,26 M
Dagbereik
€ 1,24 — € 1,29
52-Weeksbereik
€ 1,05 — € 6,75
Volume
7.293
Openen € 1,29
50D / 200D Gem.
€ 1,29
2,40% below
50D / 200D Gem.
€ 2,09
39,61% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -2,69 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-49,30%
Boven sectorgemiddelde (-51,02%)
ROIC-40,52%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio19,00
Interest CoverageN/A
Waardering
PE (TTM)
-0,73
Boven sectorgemiddelde (-1,98)
P/B Ratio0,38
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (44 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (44 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -0,7 | -2,0 |
| P/B | 0,4 | 5,1 |
| ROE % | -49,3 | -51,0 |
| Net Margin % | — | -150,2 |
| Rev Growth 5Y % | — | 9,3 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -3,11 M |
| ROE | -49,30% | ROA | -46,57% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -2,69 M |
| ROIC | -40,52% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 19,00 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 6,02 M | Tangible Book Value | 6,02 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,73 | Forward P/E | N/A |
| P/B Ratio | 0,38 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -118,97% | ||
| Market Cap | 2,26 M | Enterprise Value | 2,26 M |
| Per Share | |||
| EPS (Diluted TTM) | -2,65 | Revenue / Share | N/A |
| FCF / Share | -1,50 | OCF / Share | -1,50 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 86,56% |
| SBC-Adj. FCF | -2,92 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -3,11 M | -4,11 M | -8,95 M | -1,48 M | -1,61 M |
| EPS (Diluted) | -2,65 | -4,83 | -34,01 | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -3,23 M | -4,22 M | -9,43 M | -3,67 M | -1,10 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 1,06 M | 2,13 M | 6,91 M | 1,58 M | 82.044,0 |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | 1.868,0 | — | — |
| Income Tax | — | — | — | — | 1.600,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 5,80 M | 3,86 M | 3,74 M | 8,50 M | 6,68 M |
| Total Liabilities | 418.587,0 | 377.712,0 | 831.402,0 | 2,55 M | 99.909,0 |
| Shareholders' Equity | 5,38 M | 3,48 M | 2,91 M | 5,95 M | 6,58 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | — | — | — | — | 6,68 M |
| Current Assets | 5,80 M | 3,86 M | 3,74 M | — | — |
| Current Liabilities | 418.587,0 | 377.712,0 | 831.402,0 | 2,55 M | — |
{"event":"ticker_viewed","properties":{"ticker":"BBLG","listing_kind":"stock","pathname":"/stocks/bblg","exchange":"Nasdaq","country":"US"}}